



Yes
You
Health

Product list

June 2026

Farmaprojects
polpharma
GROUP

Under development generics

INN	PHARMACEUTICAL FORM	STRENGTH	REFERENCE PRODUCT
Alimentary tract & metabolism			
Empagliflozin*/Metformin	Film - coated tablets	5 mg / 850 mg 5 mg / 1000 mg 12.5 mg / 850 mg 12.5 mg / 1000 mg	Synjardy® (Boehringer Ingelheim)
Tirzepatide	Solution for injection	2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg	Mounjaro® (Lilly)
Allergy/Immunology			
Baricitinb*	Film - coated tablets	2 mg, 4 mg	Olumiaant® (Lilly)
Upadacitinib	Prolonged - release tablets	15 mg, 30 mg, 45 mg	Rinvoq® (Abbvie)
Respiratory System			
Fluticasone/Vilanterol*	Inhalation powder	92 mcg / 22 mcg 184 mcg / 22 mcg	Bro Ellipta® (GSK)
Umeclidinium/Vilanterol*	Inhalation powder	55 mcg / 22 mcg	Anoro Ellipta® (GSK)
Fluticasone/Umeclidinium/Vilanterol	Inhalation powder	100 mcg / 74.2 mcg / 62.5 mcg 200 mcg / 74.2mcg / 62.5 mcg	Trelegly Ellipta® (GSK)
Oxymetazoline OTC	Nasal Gel	0.25 mg/g, 0.5 mg/g	Oxalin® (Polpharma)
Xylometazoline OTC	Nasal Gel	0.1 mg/g, 1 mg/g	Otrivin® (Novartis)
Xylomethazolin e/Dexpanthenol OTC	Nasal spray solution	1.0 mg / 50 mg / ml (10ml) 0.5 mg / 50 mg / ml (10 ml)	Nasic® (Cassella-med)
Cardiology			
Bempedoic Acid	Film - Coated Tablets	180 mg	Nilemdo® (Esperion, Daiichi Sankyo)
Bempedoic Acid /Ezitimibe	Film - Coated Tablets	180 mg / 10 mg	Nustendi® (Esperion, Daiichi Sankyo)
Bempedoic Acid/Ezitimibe/Atorvastatin	Tablets	180 mg / 10 mg / 10 mg 180 mg / 10 mg / 20 mg 180 mg / 10 mg / 40 mg 180 mg / 10 mg / 80 mg	Nustendi® (Daichii Sankyo) / Lipitor® (Pfizer)
Finerenone*	Film - Coated Tablets	10 mg, 20 mg	Kerendia® (Bayer)
Ramipril	Tablets	2.5 mg, 5 mg, 10 mg	Delix® (Sanofi)
Valsartan	Film - coated tablets	40 mg, 80 mg, 160 mg, 320 mg	Diovan® (Novartis)

*Polpharma Group API

CA: Dossier suitable for Canadian market

Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subjected to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement.

It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s).

Based on exemption under art.5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Ticagrelor, Dapagliflozin and Linagliptin, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met.

Valsartan/Hydrochlorothiazide	Film - coated tablets	80 mg/12.5 mg 160 mg / 12.5 mg 160 mg / 25 mg 320 mg /12.5 mg 320 mg /25 mg	Codiovon® (Novartis)
Short RNA (Oligonucleotide)			
Nusinersen*	Solution for injection	12 mg / 5 ml vial (2.4 mg/ml)	Spinraza® (Biogen)
Inclisiran	Solution for injection (pre-filled syringe)	284 mg / 1.5 mL (189 mg/mL)	Leqvio® (Novartis)
Central Nervous System			
Cenobamate	Film - coated tablets	12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, 200 mg	Ontozry® (SK Biopharmaceuticals)
Cenobamate	Oral Solution (first-in-market)	10 mg/mL	Ontozry® (SK Biopharmaceuticals)
Endocrinology			
Osilodrostat	Tablets	1 mg, 5 mg, 10 mg	Istursia® (Recordati)
Dermatology			
Minoxidil OTC	Foam	0.05	Regaine® (Johnson&Johnson)
Gynecology			
Progesterone	Solution for injection	25 mg / 1.112 mL	Lubion® (IBSA)

Available

INN	PHARMACEUTICAL FORM	STRENGTH	REFERENCE PRODUCT	LACTOSE FREE	STABILITY	SHELF LIFE
Alimentary tract & metabolism						
Dapagliflozin* / Metformin	Film - coated tablets	5 mg / 850 mg 5 mg / 1000 mg	Xigduo® (AstraZeneca)	Yes	II: available IVb: available	36 months
Dapagliflozin*	Film - coated tablets	5 mg, 10 mg	Forxiga® (AstraZeneca)	Yes	II: available IVb: available	36 months

*Polpharma Group API

CA: Dossier suitable for Canadian market

Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subjected to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement.

It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s).

Based on exemption under art.5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Ticagrelor, Dapagliflozin and Linagliptin, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met.

Empagliflozin*	Film - coated tablets	10 mg, 25 mg	Jardiance® (Boehringer Ingelheim)	Yes	II: available IVb: available	36 months / Do not store above 30 °C
Linagliptin*	Film - coated tablets	5 mg	Trajenta® (Boehringer Ingelheim)	Yes	II: available IVb: available	36 months
Orlistat	Hard capsules	120 mg	Xenical® (Roche)	Yes	II: available IVb: not available	24 months
Orlistat OTC	Hard capsules	60 mg	Alli® (GSK)	Yes	II: available IVb: not available	24 months
Sitagliptin*	Film - coated tablets	25 mg, 50 mg, 100 mg	Januvia® (Merck)	Yes	II: available IVb: available	36 months
Sitagliptin*/Metformin	Film - coated tablets	50 mg / 850 mg / 50 mg / 1000 mg	Janumet® (Merck)	Yes	II: available IVb: available	24 months
Anti-infectives for systemic use						
Aciclovir	Tablets	200 mg, 400 mg, 800 mg	Zovirax® (GSK)	Yes	II: available IVb: not available	36 months
Antineoplastic & Immunomodulating Agents						
Apremilast*	Film - coated tablets	10 mg, 20 mg, 30 mg	Otezla® (Celgene)	Yes	II: available IVb: not available	36 months
Blood & Blood forming organs						

*Polpharma Group API

CA: Dossier suitable for Canadian market

Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subjected to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement.

It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s).

Based on exemption under art.5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Ticagrelor, Dapagliflozin and Linagliptin, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met.

Apixaban*	Film - coated tablets	2.5 mg, 5 mg	Eliquis® (Bristol-Myers Squibb)	No	II: available IVb: available	36 months
Rivaroxaban*	Film - coated tablets	2.5 mg, 10 mg, 15 mg, 20 mg	Xarelto® (Bayer)	No	II: on-going IVb: on-going	24 months
Rivaroxaban*	Capsules	10 mg, 15 mg, 20 mg	Xarelto® (Bayer)	No	II: available	24 months
Ticagrelor*	Film - coated tablets	60 mg, 90 mg	Brilique® (AstraZeneca)	Yes	II: available IVb: available	36 months

Cardiovascular System

Ramipril / Indapamide	Hard capsules (IR dosage form)	5 mg / 2.5 mg 10 mg / 2.5 mg 5 mg / 1.25 mg 10 mg / 1.25 mg	New combination	No	II: available	36 months
Hydrochlorothiazide*	Tablets	12.5 mg, 25 mg, 50 mg	Esidrex® (Novartis)	No	II: available IVb: not available	60 months
Ramipril / Amlodipine	Hard capsules	5 mg / 5 mg 5 mg / 10 mg 10 mg / 5 mg 10 mg / 10 mg	Tritace® / Ramipril (Sanofi) & Norvasc® / Amlodipine (Pfizer)	Yes	II: available IVb: not available	36 months
Rosuvastatin	Film - coated tablets	5 mg, 10 mg, 20 mg	Crestor® (AstraZeneca)	No	II: available IVa: available IVb: not available	36 months (Zone II) 12 months (Zone IVa)

*Polpharma Group API

CA: Dossier suitable for Canadian market

Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subjected to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement.

It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s).

Based on exemption under art.5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Ticagrelor, Dapagliflozin and Linagliptin, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met.

Telmisartan / Amlodipine	Bilayered Tablets	40 mg / 5 mg 40 mg / 10 mg 80 mg / 5 mg 80 mg / 10 mg	Twynsta® (Boehringer Ingelheim)	Yes	II: available IVb: available	36 months
-----------------------------	----------------------	--	---------------------------------------	-----	---------------------------------------	-----------

Dermatology

Dimetindene	Gel	1 mg /g (20g) 1 mg /g (30g) 1 mg /g (50g)	Fenistil(TM) (Novartis)	Yes	II: available IVb: available	36 months
-------------	-----	--	----------------------------	-----	---------------------------------------	-----------

Genito-Urinary System & Sex Hormones

Tadalafil*	Film-coated tablets	2.5 mg, 5 mg, 10 mg, 20 mg	Cialis® (Eli Lilly)	No	II: available IVb: available	48 months
------------	------------------------	-------------------------------------	------------------------	----	---------------------------------------	-----------

Musculoskeletal System

Paracetamol/ Ibuprofen	Film-coated tablets	500 mg / 200 mg	Nurofen Ultima® (Reckitt Benckiser)		II: available IVb: ongoing	36 months
---------------------------	------------------------	--------------------	--	--	-------------------------------------	--------------

Nervous System

Dimethyl Fumarate	Gastro-resistant hard capsules	120 mg, 240 mg	Tecfidera® (Biogen Idec)	Yes	II: ongoing IVb: ongoing	36 months / Do not store above 30 °C (zone II) 24 months / Do not store above 30 °C (zone IV)
----------------------	-----------------------------------	-------------------	--------------------------------	-----	-----------------------------------	--

Memantine hydrochloride	Film-coated tablets	10 mg, 20 mg	Ebixa® (Lundbeck)	No	II: available IVa: available	36 months	Store below 30°C. After first opening use in 90 days.	43 86 0	Olo don® /Nolo don®/ Starel Itec®	Olod on® /Nolo don®/ Starel Itec®
----------------------------	------------------------	-----------------	----------------------	----	---------------------------------------	-----------	---	---------------	--	--

*Polpharma Group API

CA: Dossier suitable for Canadian market

Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subjected to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement.

It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s).

Based on exemption under art.5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Ticagrelor, Dapagliflozin and Linagliptin, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met.

Once opened - store for 28 days at a temperature below 30oC

40
00
0

Floxamic® / Ekara® / Genaxil®

Quetiapine

Film-coated tablets

25 mg,
100 mg,
150 mg,
200 mg,
300 mg

Seroquel® (AstraZeneca)

No

II: available IVb: available

36 months

Respiratory System

Glycopyrronium

Inhalation powder

44 mcg

Seebri Breezhale r® (Novartis)

No

II: available

24 months

Once opened, do not store above 25oC

70
42
3
25
51
0

Bimifrene®

Bimi® / Iricryn®

Glycopyrronium / Indacaterol

Inhalation powder

43 mcg / 85 mcg

Ultibro Breezhale r® (Novartis)

No

II: available IVb: available

24 months

Once opened, do not store above 25oC

70
42
3
25
51
0

Bimifrene® / Combimbi®

Bimido® / Bapiri® / Bitifrine®

Vitamins & Minerals

Cholecalciferol (Vitamin D3)

Soft capsule

20.000 IU

N/A

Yes

II: available IVa: not available

36 months

Store below 30oC. After first opening use in 90 days.

43
10
3
43
10
3

Briglau® / PPH Fre®

Brigla u® / Briglafre® / Rivotara®

*Polpharma Group API

CA: Dossier suitable for Canadian market

Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subjected to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement.

It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s).

Based on exemption under art.5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Ticagrelor, Dapagliflozin and Linagliptin, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met.



FARMAPROJECTS SAU
Carrer Provença 392, 6ª Planta
08025 Barcelona (Spain)
Phone +34 93 508 05 00
email: sales@farmaprojects.com

www.farmaprojects.com

